Effect of PPAR α/γ agonist on Behavioural Alterations in 6-OHDA induced Parkinson Disease

Abstract

AIM- The aim of present research work aimed to investigate the neuroprotective potential of saroglitazor in experimental animal model of neurodegenerative disease. MATERIAL & METHODS- Sixty Male Wistar albino rats (150-200 gm) were obtained from the Central Animal House of Pharmaceutical Sciences, India. The tablets of 4 mg Saroglitazar (SG), were weighed and finely powdered and then transferred into a 10-ml calibrated flask, dissolved in 4 ml sterile saline solution (0.9% NaCl), swirled and sonicated for 5 min, completed to volume with saline, and shaken well for 15 min immediately before administration. For the post operative care, Povidone-iodine was applied to all the animals for one week after surgery and gentamycin (7 mg/kg) were given to all animals 24 hourly for 2 days. The Rota rod unit consists of a rotating rod, 48 mm in diameter, which was divided into four parts by compartmentalization to permit the testing of four rats at a time. RESULTS- DC group showed marked (p < 0.0001) decline in fall off time as compared to NC group. On the other hand, SG-1, SG-3 and SG-10 groups showed dose dependent remarkable (p< 0.005, p<0.0001, respectively) rise in fall off time when compared to DC group. SG-1, SG-3 and SG-10 groups showed drastic (p < 0.0001) growth in forehand adjusting steps and noticeable (p < 0.001) increment in backhand adjusting steps with exception of non significant rise with SG-1 group, when compared to DC group. CONCLUSION- In brief, for the first time we report that novel dual PPAR α/γ agonist, SG inhibited 6-OHDA-induced dopaminergic Neurodegeneration and mitigated behavioral alterations in rat model of PD.
 Keywords: Dopaminergic Neurodegeneration, Saroglitazar, Parkinson’s disease, Substantia nigra pars, Compacta region